WO2014098232A1 - Composition pharmaceutique comprenant un inhibiteur de kinase pi3, composition pharmaceutique comprenant un composé qui agit sur un récepteur de vitamine d, composition lyophilisée, procédé de production de composition lyophilisée et composition pharmaceutique destinée à être administrée par voie transpulmonaire - Google Patents
Composition pharmaceutique comprenant un inhibiteur de kinase pi3, composition pharmaceutique comprenant un composé qui agit sur un récepteur de vitamine d, composition lyophilisée, procédé de production de composition lyophilisée et composition pharmaceutique destinée à être administrée par voie transpulmonaire Download PDFInfo
- Publication number
- WO2014098232A1 WO2014098232A1 PCT/JP2013/084310 JP2013084310W WO2014098232A1 WO 2014098232 A1 WO2014098232 A1 WO 2014098232A1 JP 2013084310 W JP2013084310 W JP 2013084310W WO 2014098232 A1 WO2014098232 A1 WO 2014098232A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- freeze
- composition
- pharmaceutical composition
- vitamin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 195
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 116
- 150000001875 compounds Chemical class 0.000 title claims abstract description 84
- 102000009310 vitamin D receptors Human genes 0.000 title claims abstract description 59
- 108050000156 vitamin D receptors Proteins 0.000 title claims abstract description 59
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title claims abstract description 24
- 229940116355 PI3 kinase inhibitor Drugs 0.000 title claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 title claims description 39
- 150000001413 amino acids Chemical class 0.000 claims abstract description 114
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 97
- 239000004094 surface-active agent Substances 0.000 claims abstract description 72
- 239000003814 drug Substances 0.000 claims abstract description 71
- 229940079593 drug Drugs 0.000 claims abstract description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 61
- 239000004480 active ingredient Substances 0.000 claims abstract description 58
- 239000002245 particle Substances 0.000 claims description 128
- 229940024606 amino acid Drugs 0.000 claims description 113
- 235000001014 amino acid Nutrition 0.000 claims description 113
- 239000007788 liquid Substances 0.000 claims description 80
- 210000000130 stem cell Anatomy 0.000 claims description 70
- 239000003795 chemical substances by application Substances 0.000 claims description 67
- 210000004072 lung Anatomy 0.000 claims description 65
- 230000004069 differentiation Effects 0.000 claims description 60
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 55
- 230000001939 inductive effect Effects 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 43
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 32
- 230000000451 tissue damage Effects 0.000 claims description 32
- 231100000827 tissue damage Toxicity 0.000 claims description 32
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 29
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 27
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 23
- 239000004471 Glycine Substances 0.000 claims description 22
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 19
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 19
- 235000004279 alanine Nutrition 0.000 claims description 19
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 19
- 229960000310 isoleucine Drugs 0.000 claims description 19
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 19
- 238000004108 freeze drying Methods 0.000 claims description 18
- 239000000411 inducer Substances 0.000 claims description 17
- 230000008929 regeneration Effects 0.000 claims description 16
- 238000011069 regeneration method Methods 0.000 claims description 16
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 15
- 239000004474 valine Substances 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 13
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 13
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 7
- 235000013734 beta-carotene Nutrition 0.000 claims description 7
- 239000011648 beta-carotene Substances 0.000 claims description 7
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 6
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 claims description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 5
- 235000019155 vitamin A Nutrition 0.000 claims description 5
- 239000011719 vitamin A Substances 0.000 claims description 5
- 229940045997 vitamin a Drugs 0.000 claims description 5
- 230000037361 pathway Effects 0.000 description 69
- 230000002685 pulmonary effect Effects 0.000 description 52
- 239000000243 solution Substances 0.000 description 48
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 44
- 229930002330 retinoic acid Natural products 0.000 description 43
- 239000002609 medium Substances 0.000 description 34
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 33
- 239000006185 dispersion Substances 0.000 description 30
- 239000012828 PI3K inhibitor Substances 0.000 description 28
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 28
- 238000002360 preparation method Methods 0.000 description 26
- 150000003710 vitamin D derivatives Chemical class 0.000 description 24
- -1 inositol phospholipid Chemical class 0.000 description 21
- 239000011710 vitamin D Substances 0.000 description 19
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 18
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 16
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 16
- 229930003316 Vitamin D Natural products 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 235000019166 vitamin D Nutrition 0.000 description 16
- 229940046008 vitamin d Drugs 0.000 description 16
- 239000000843 powder Substances 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000000654 additive Substances 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 11
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 11
- 108090000976 Aquaporin 5 Proteins 0.000 description 10
- 206010014561 Emphysema Diseases 0.000 description 10
- 102100037280 Aquaporin-5 Human genes 0.000 description 9
- 241000283707 Capra Species 0.000 description 9
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 9
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 8
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 8
- 230000000996 additive effect Effects 0.000 description 8
- 210000002383 alveolar type I cell Anatomy 0.000 description 8
- 210000002588 alveolar type II cell Anatomy 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000007884 disintegrant Substances 0.000 description 8
- 239000000314 lubricant Substances 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 8
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 7
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
- 229920000053 polysorbate 80 Polymers 0.000 description 7
- 230000007730 Akt signaling Effects 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108091007960 PI3Ks Proteins 0.000 description 6
- 102000016387 Pancreatic elastase Human genes 0.000 description 6
- 108010067372 Pancreatic elastase Proteins 0.000 description 6
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 6
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 6
- 238000012795 verification Methods 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- NSTPXGARCQOSAU-VIFPVBQESA-N N-formyl-L-phenylalanine Chemical compound O=CN[C@H](C(=O)O)CC1=CC=CC=C1 NSTPXGARCQOSAU-VIFPVBQESA-N 0.000 description 5
- 102000038030 PI3Ks Human genes 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- SQWZFLMPDUSYGV-POHAHGRESA-N (5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=C(N=CC=N2)C2=C1 SQWZFLMPDUSYGV-POHAHGRESA-N 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- 206010006458 Bronchitis chronic Diseases 0.000 description 4
- 235000021318 Calcifediol Nutrition 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 208000007451 chronic bronchitis Diseases 0.000 description 4
- 230000009429 distress Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 206010035653 pneumoconiosis Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000003456 pulmonary alveoli Anatomy 0.000 description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 description 4
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 208000029523 Interstitial Lung disease Diseases 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102100023617 Neutrophil cytosol factor 4 Human genes 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 108091008611 Protein Kinase B Proteins 0.000 description 3
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000012888 bovine serum Substances 0.000 description 3
- 229960005084 calcitriol Drugs 0.000 description 3
- 235000020964 calcitriol Nutrition 0.000 description 3
- 239000011612 calcitriol Substances 0.000 description 3
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 3
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229960002061 ergocalciferol Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 3
- 108010086154 neutrophil cytosol factor 40K Proteins 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000001892 vitamin D2 Nutrition 0.000 description 3
- 239000011653 vitamin D2 Substances 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 2
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 description 2
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 2
- YOVVNQKCSKSHKT-HNNXBMFYSA-N (2s)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one Chemical compound C1CN(C(=O)[C@@H](O)C)CCN1CC1=C(C)C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2S1 YOVVNQKCSKSHKT-HNNXBMFYSA-N 0.000 description 2
- SRLVNYDXMUGOFI-YWEYNIOJSA-N (5e)-5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2OC(F)(F)OC2=CC=C1\C=C1/SC(=O)NC1=O SRLVNYDXMUGOFI-YWEYNIOJSA-N 0.000 description 2
- UFBTYTGRUBUUIL-KPKJPENVSA-N (5e)-5-[[5-(4-fluorophenyl)furan-2-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(F)=CC=C1C(O1)=CC=C1\C=C\1C(=O)NC(=O)S/1 UFBTYTGRUBUUIL-KPKJPENVSA-N 0.000 description 2
- QDITZBLZQQZVEE-YBEGLDIGSA-N (5z)-5-[(4-pyridin-4-ylquinolin-6-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=C(N=CC=C2C=3C=CN=CC=3)C2=C1 QDITZBLZQQZVEE-YBEGLDIGSA-N 0.000 description 2
- OYYVWNDMOQPMGE-SDQBBNPISA-N (5z)-5-[[5-(4-fluoro-2-hydroxyphenyl)furan-2-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound OC1=CC(F)=CC=C1C(O1)=CC=C1\C=C/1C(=O)NC(=O)S\1 OYYVWNDMOQPMGE-SDQBBNPISA-N 0.000 description 2
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 2
- ZAXFYGBKZSQBIV-UHFFFAOYSA-N 1-[4-(3-ethyl-7-morpholin-4-yltriazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-[4-(4-methylpiperazine-1-carbonyl)phenyl]urea Chemical compound N1=C2N(CC)N=NC2=C(N2CCOCC2)N=C1C(C=C1)=CC=C1NC(=O)NC(C=C1)=CC=C1C(=O)N1CCN(C)CC1 ZAXFYGBKZSQBIV-UHFFFAOYSA-N 0.000 description 2
- DWZAEMINVBZMHQ-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CCOCC2)N2CCOCC2)C=C1 DWZAEMINVBZMHQ-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- KQDBVHKNIYROHU-UHFFFAOYSA-N 2-[(4-aminopyrazolo[3,4-d]pyrimidin-1-yl)methyl]-5-methyl-3-(2-methylphenyl)quinazolin-4-one Chemical compound CC1=CC=CC=C1N1C(=O)C2=C(C)C=CC=C2N=C1CN1C2=NC=NC(N)=C2C=N1 KQDBVHKNIYROHU-UHFFFAOYSA-N 0.000 description 2
- IRTDIKMSKMREGO-OAHLLOKOSA-N 2-[[(1R)-1-[7-methyl-2-(4-morpholinyl)-4-oxo-9-pyrido[1,2-a]pyrimidinyl]ethyl]amino]benzoic acid Chemical compound N([C@H](C)C=1C=2N(C(C=C(N=2)N2CCOCC2)=O)C=C(C)C=1)C1=CC=CC=C1C(O)=O IRTDIKMSKMREGO-OAHLLOKOSA-N 0.000 description 2
- WFSLJOPRIJSOJR-UHFFFAOYSA-N 2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-methyl-3-(2-methylphenyl)quinazolin-4-one Chemical compound CC1=CC=CC=C1N1C(=O)C2=C(C)C=CC=C2N=C1CN1C2=NC=NC(N)=C2C(C=2C=C(O)C=CC=2)=N1 WFSLJOPRIJSOJR-UHFFFAOYSA-N 0.000 description 2
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 2
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 description 2
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 2
- 239000003872 25-hydroxy-cholecalciferol Substances 0.000 description 2
- UJIAQDJKSXQLIT-UHFFFAOYSA-N 3-[2,4-diamino-7-(3-hydroxyphenyl)-6-pteridinyl]phenol Chemical compound C=1C=CC(O)=CC=1C1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC(O)=C1 UJIAQDJKSXQLIT-UHFFFAOYSA-N 0.000 description 2
- FSASIHFSFGAIJM-UHFFFAOYSA-N 3-methyladenine Chemical compound CN1C=NC(N)=C2N=CN=C12 FSASIHFSFGAIJM-UHFFFAOYSA-N 0.000 description 2
- RZIDZIGAXXNODG-UHFFFAOYSA-N 4-[(4-chlorophenyl)methyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amine Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CCC1(N)CC1=CC=C(Cl)C=C1 RZIDZIGAXXNODG-UHFFFAOYSA-N 0.000 description 2
- BYWWNRBKPCPJMG-UHFFFAOYSA-N 4-dodecyl-n-(1,3,4-thiadiazol-2-yl)benzenesulfonamide Chemical compound C1=CC(CCCCCCCCCCCC)=CC=C1S(=O)(=O)NC1=NN=CS1 BYWWNRBKPCPJMG-UHFFFAOYSA-N 0.000 description 2
- RXRZPHQBTHQXSV-UHFFFAOYSA-N 5-(2-amino-8-fluoro-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-n-tert-butylpyridine-3-sulfonamide Chemical compound CC(C)(C)NS(=O)(=O)C1=CN=CC(C2=CN3N=C(N)N=C3C(F)=C2)=C1 RXRZPHQBTHQXSV-UHFFFAOYSA-N 0.000 description 2
- JEGHXKRHKHPBJD-UHFFFAOYSA-N 5-(7-methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine Chemical compound CS(=O)(=O)N1CCC2=C1N=C(N1CCOCC1)N=C2C1=CN=C(N)N=C1 JEGHXKRHKHPBJD-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 2
- CPRAGQJXBLMUEL-UHFFFAOYSA-N 9-(1-anilinoethyl)-7-methyl-2-(4-morpholinyl)-4-pyrido[1,2-a]pyrimidinone Chemical compound C=1C(C)=CN(C(C=C(N=2)N3CCOCC3)=O)C=2C=1C(C)NC1=CC=CC=C1 CPRAGQJXBLMUEL-UHFFFAOYSA-N 0.000 description 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 2
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- GNWHRHGTIBRNSM-UHFFFAOYSA-N IC-87114 Chemical compound CC1=CC=CC=C1N1C(=O)C2=C(C)C=CC=C2N=C1CN1C2=NC=NC(N)=C2N=C1 GNWHRHGTIBRNSM-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 2
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- ULDXWLCXEDXJGE-UHFFFAOYSA-N MK-2206 Chemical compound C=1C=C(C=2C(=CC=3C=4N(C(NN=4)=O)C=CC=3N=2)C=2C=CC=CC=2)C=CC=1C1(N)CCC1 ULDXWLCXEDXJGE-UHFFFAOYSA-N 0.000 description 2
- 229940124640 MK-2206 Drugs 0.000 description 2
- FCKJZIRDZMVDEM-UHFFFAOYSA-N N-(7,8-dimethoxy-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene)pyridine-3-carboxamide Chemical compound COC1=C(C2=NC(=NC(=O)C3=CN=CC=C3)N4CCNC4=C2C=C1)OC FCKJZIRDZMVDEM-UHFFFAOYSA-N 0.000 description 2
- DMMILYKXNCVKOJ-UHFFFAOYSA-N N-[3-[[5-bromo-4-[2-(1H-imidazol-5-yl)ethylamino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide Chemical compound N1=C(NCCC=2N=CNC=2)C(Br)=CN=C1NC(C=1)=CC=CC=1NC(=O)N1CCCC1 DMMILYKXNCVKOJ-UHFFFAOYSA-N 0.000 description 2
- VAVXGGRQQJZYBL-UHFFFAOYSA-N N-[3-[[5-iodo-4-[3-[[oxo(thiophen-2-yl)methyl]amino]propylamino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide Chemical compound N1=C(NCCCNC(=O)C=2SC=CC=2)C(I)=CN=C1NC(C=1)=CC=CC=1NC(=O)N1CCCC1 VAVXGGRQQJZYBL-UHFFFAOYSA-N 0.000 description 2
- YULUCECVQOCQFQ-UHFFFAOYSA-N OSU-03012 Chemical compound C1=CC(NC(=O)CN)=CC=C1N1C(C=2C=C3C(C4=CC=CC=C4C=C3)=CC=2)=CC(C(F)(F)F)=N1 YULUCECVQOCQFQ-UHFFFAOYSA-N 0.000 description 2
- 102000008108 Osteoprotegerin Human genes 0.000 description 2
- 108010035042 Osteoprotegerin Proteins 0.000 description 2
- TUVCWJQQGGETHL-UHFFFAOYSA-N PI-103 Chemical compound OC1=CC=CC(C=2N=C3C4=CC=CN=C4OC3=C(N3CCOCC3)N=2)=C1 TUVCWJQQGGETHL-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 2
- 239000004147 Sorbitan trioleate Substances 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- HJSSPYJVWLTYHG-UHFFFAOYSA-N XL765 Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC(NC(=O)C=3C=C(OC)C(C)=CC=3)=CC=2)=C1 HJSSPYJVWLTYHG-UHFFFAOYSA-N 0.000 description 2
- HGVNLRPZOWWDKD-UHFFFAOYSA-N ZSTK-474 Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- 229950010482 alpelisib Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229950003628 buparlisib Drugs 0.000 description 2
- 229960004361 calcifediol Drugs 0.000 description 2
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 2
- 229960002882 calcipotriol Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- PZBCKZWLPGJMAO-UHFFFAOYSA-N copanlisib Chemical compound C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 229950006418 dactolisib Drugs 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 229960003445 idelalisib Drugs 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 229940126401 izorlisib Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VOUDEIAYNKZQKM-MYHMWQFYSA-N n-[(e)-(6-bromoimidazo[1,2-a]pyridin-3-yl)methylideneamino]-n,2-dimethyl-5-nitrobenzenesulfonamide;hydrochloride Chemical compound Cl.C=1N=C2C=CC(Br)=CN2C=1/C=N/N(C)S(=O)(=O)C1=CC([N+]([O-])=O)=CC=C1C VOUDEIAYNKZQKM-MYHMWQFYSA-N 0.000 description 2
- JFVNFXCESCXMBC-UHFFFAOYSA-N n-[5-[4-chloro-3-(2-hydroxyethylsulfamoyl)phenyl]-4-methyl-1,3-thiazol-2-yl]acetamide Chemical compound S1C(=N/C(=O)C)\NC(C)=C1C1=CC=C(Cl)C(S(=O)(=O)NCCO)=C1 JFVNFXCESCXMBC-UHFFFAOYSA-N 0.000 description 2
- JOWXJLIFIIOYMS-UHFFFAOYSA-N n-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound C1=NC(OC)=CC=C1C1=NC(N2CCOCC2)=C(SC(CN(C)C=2N=CC(=CN=2)C(=O)NO)=C2)C2=N1 JOWXJLIFIIOYMS-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 2
- YUGCAAVRZWBXEQ-WHTXLNIXSA-N previtamin D3 Chemical compound C=1([C@@H]2CC[C@@H]([C@]2(CCC=1)C)[C@H](C)CCCC(C)C)\C=C/C1=C(C)CC[C@H](O)C1 YUGCAAVRZWBXEQ-WHTXLNIXSA-N 0.000 description 2
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 2
- 210000004879 pulmonary tissue Anatomy 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 description 2
- 229960000391 sorbitan trioleate Drugs 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 229960004907 tacalcitol Drugs 0.000 description 2
- BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 description 2
- 229950001269 taselisib Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- HBPXWEPKNBHKAX-NSHDSACASA-N (2S)-N1-[5-(2-tert-butyl-4-thiazolyl)-4-methyl-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2N=C(SC=2)C(C)(C)C)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O HBPXWEPKNBHKAX-NSHDSACASA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- UOORQSPLBHUQDQ-UHFFFAOYSA-N 3-(2,4-diaminopteridin-6-yl)phenol Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC(O)=C1 UOORQSPLBHUQDQ-UHFFFAOYSA-N 0.000 description 1
- YBPIBGNBHHGLEB-UHFFFAOYSA-N 6-amino-N-[3-[4-(4-morpholinyl)-2-pyrido[2,3]furo[2,4-b]pyrimidinyl]phenyl]-3-pyridinecarboxamide Chemical compound C1=NC(N)=CC=C1C(=O)NC1=CC=CC(C=2N=C3C4=CC=CN=C4OC3=C(N3CCOCC3)N=2)=C1 YBPIBGNBHHGLEB-UHFFFAOYSA-N 0.000 description 1
- YEAHTLOYHVWAKW-UHFFFAOYSA-N 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one Chemical compound C1=CC(OC)=CC=C1COC(C(=C1)OC)=CC2=C1C1=CC=C(C(C)O)C=C1C(=O)O2 YEAHTLOYHVWAKW-UHFFFAOYSA-N 0.000 description 1
- JAMULYFATHSZJM-UHFFFAOYSA-N 8-(4-dibenzothiophenyl)-2-(4-morpholinyl)-1-benzopyran-4-one Chemical compound O1C2=C(C=3C=4SC5=CC=CC=C5C=4C=CC=3)C=CC=C2C(=O)C=C1N1CCOCC1 JAMULYFATHSZJM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- 102000004392 Aquaporin 5 Human genes 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- YUXMAKUNSXIEKN-BTJKTKAUSA-N BGT226 Chemical compound OC(=O)\C=C/C(O)=O.C1=NC(OC)=CC=C1C1=CC=C(N=CC2=C3N(C=4C=C(C(N5CCNCC5)=CC=4)C(F)(F)F)C(=O)N2C)C3=C1 YUXMAKUNSXIEKN-BTJKTKAUSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- TXDUTHBFYKGSAH-SFHVURJKSA-N Evodiamine Chemical compound C1=CC=C2N(C)[C@@H]3C(NC=4C5=CC=CC=4)=C5CCN3C(=O)C2=C1 TXDUTHBFYKGSAH-SFHVURJKSA-N 0.000 description 1
- HMXRXBIGGYUEAX-SFHVURJKSA-N Evodiamine Natural products CN1[C@H]2N(CCc3[nH]c4ccccc4c23)C(=O)c5ccccc15 HMXRXBIGGYUEAX-SFHVURJKSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 102000010498 Receptor Activator of Nuclear Factor-kappa B Human genes 0.000 description 1
- 108010038036 Receptor Activator of Nuclear Factor-kappa B Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940009100 aurothiomalate Drugs 0.000 description 1
- XJHSMFDIQHVMCY-UHFFFAOYSA-M aurothiomalic acid Chemical compound OC(=O)CC(S[Au])C(O)=O XJHSMFDIQHVMCY-UHFFFAOYSA-M 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- XDLYKKIQACFMJG-WKILWMFISA-N chembl1234354 Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1[C@@H]1CC[C@@H](OCCO)CC1 XDLYKKIQACFMJG-WKILWMFISA-N 0.000 description 1
- 238000004883 computer application Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- QTHCAAFKVUWAFI-DJKKODMXSA-N n-[(e)-(6-bromoimidazo[1,2-a]pyridin-3-yl)methylideneamino]-n,2-dimethyl-5-nitrobenzenesulfonamide Chemical compound C=1N=C2C=CC(Br)=CN2C=1/C=N/N(C)S(=O)(=O)C1=CC([N+]([O-])=O)=CC=C1C QTHCAAFKVUWAFI-DJKKODMXSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229960000987 paricalcitol Drugs 0.000 description 1
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 description 1
- 150000003916 phosphatidylinositol 3,4,5-trisphosphates Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229950010130 tamibarotene Drugs 0.000 description 1
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000002266 vitamin A derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Definitions
- the present invention relates to a pharmaceutical composition containing a PI3 kinase inhibitor, a pharmaceutical composition containing a compound acting on a vitamin D receptor, a lyophilized composition for producing a pharmaceutical composition for pulmonary administration, and the lyophilized composition And a pharmaceutical composition for pulmonary administration.
- COPD chronic obstructive pulmonary disease
- pulmonary emphysema chronic bronchitis
- acute lung distress syndrome (ARDS) acute lung distress syndrome
- pulmonary fibrosis lung cancer
- stroma Pneumonia pulmonary tuberculosis sequelae
- pneumoconiosis etc.
- COPD chronic obstructive pulmonary disease
- ARDS acute lung distress syndrome
- pulmonary fibrosis lung cancer
- stroma Pneumonia pulmonary tuberculosis sequelae
- pneumoconiosis etc.
- a therapeutic agent that induces differentiation of alveolar epithelial stem cells into type I and type II alveolar epithelial cells constituting the alveoli and regenerates the alveoli is considered promising. It has been.
- an inhalation system for powder medicine for pulmonary administration there is an inhalation system that particles a freeze-dried composition by air impact (see, for example, US Pat. No. 7,735,485 B2 and US Pat. No. 4,822,709).
- the freeze-dried composition becomes particles suitable for transpulmonary administration by inhalation of the patient, and inhalation is performed as it is to perform transpulmonary administration.
- this system uses a lyophilization method suitable for water-soluble drugs, such as proteins and peptides, and is suitable for transpulmonary formulation of drugs that are poorly soluble in water such as retinoic acid. Not. Therefore, in order to apply this system to poorly soluble drugs such as retinoic acid, it is necessary to find a new formulation and manufacturing method.
- a compound that induces differentiation of alveolar epithelial stem cells into alveolar epithelial cells has been found and the compound can be formulated into a pharmaceutical composition for transpulmonary administration, regeneration of alveoli will be possible for diseases exhibiting lung tissue damage. It is possible to provide a treatment method having an action point.
- a mode of administration of a pharmaceutical composition for pulmonary administration if the powder drug inhalation system for pulmonary administration disclosed in US Pat. No. 7,735,485B2 or US Pat. A regenerative therapy for alveoli can be provided simply.
- the present invention was made under the above situation.
- a differentiation inducer that acts on alveolar epithelial stem cells comprising a PI3 kinase inhibitor as an active ingredient.
- a pharmaceutical composition for inducing alveolar regeneration comprising a PI3 kinase inhibitor as an active ingredient.
- a pharmaceutical composition for treating lung tissue injury comprising a PI3 kinase inhibitor as an active ingredient.
- A5 Use of a PI3 kinase inhibitor in the manufacture of a pharmaceutical composition that induces alveolar regeneration.
- A6 Use of a PI3 kinase inhibitor in the manufacture of a pharmaceutical composition for treating lung tissue damage.
- PI3 kinase inhibitor for use in the treatment of lung tissue damage.
- a method for treating lung tissue damage comprising administering a pharmaceutical composition comprising a PI3 kinase inhibitor as an active ingredient to a patient having damage to lung tissue.
- the PI3 kinase inhibitor is an agent that directly inhibits PI3 kinase, an agent that inhibits the PI3K-Akt pathway, an agent that inhibits the PI3K-BTK pathway, an agent that inhibits the PI3K-ITK pathway, PI3K-TAPP1 Agents that inhibit the pathway, agents that inhibit the PI3K-DAPP pathway, agents that inhibit the PI3K-GAB1 / 2 pathway, agents that inhibit the PI3K-Rac pathway, agents that inhibit the PI3K-Rho pathway, and inhibitors the PI3K-ARF pathway Agents that inhibit the PI3K-PDK1 pathway, agents that inhibit the PI3K-EEA1 pathway, agents that inhibit the PI3K-Rabenosyn5 pathway, agents that inhibit the PI3K-Rabip4 pathway, agents that inhibit the PI3K-FAB1 pathway, PI3K- PI3, an agent that inhibits the p40phox pathway Agent
- a differentiation inducer that acts on alveolar epithelial stem cells comprising a compound that acts on a vitamin D receptor as an active ingredient.
- B2 A pharmaceutical composition for inducing alveolar regeneration, comprising a compound that acts on a vitamin D receptor as an active ingredient.
- B3 A pharmaceutical composition for treating lung tissue damage, comprising a compound that acts on a vitamin D receptor as an active ingredient.
- B4 Use of a compound that acts on a vitamin D receptor in the production of a differentiation inducer that acts on alveolar epithelial stem cells.
- B5 Use of a compound that acts on a vitamin D receptor in the manufacture of a pharmaceutical composition that induces alveolar regeneration.
- (B6) Use of a compound that acts on a vitamin D receptor in the manufacture of a pharmaceutical composition for treating lung tissue damage.
- a method for treating lung tissue damage comprising administering to a patient having damage to lung tissue a pharmaceutical composition comprising a compound that acts on a vitamin D receptor as an active ingredient.
- the compound acting on the vitamin D receptor is vitamin D 2 and derivatives thereof, vitamin D 3 and derivatives thereof, vitamin D 4 and derivatives thereof, vitamin D 5 and derivatives thereof, vitamin D 6 and derivatives thereof, vitamins is at least one member selected from D 7 and derivatives thereof, wherein (B1) ⁇ (B8).
- (C1) Freeze-drying that contains a poorly water-soluble drug, at least two types of amino acids, and a surfactant, and the proportion of particles having a particle diameter of 5 ⁇ m or less becomes 10% or more when formed into particles by air flow Composition.
- (C101) contains a poorly water-soluble drug, at least two types of amino acids, and a surfactant, and when formed into particles by an air stream, the proportion of particles having a geometric particle diameter of 5 ⁇ m or less is 10% or more.
- a lyophilized composition is a poorly water-soluble drug, at least two types of amino acids, and a surfactant
- (C102) contains a poorly water-soluble drug, at least two kinds of amino acids, and a surfactant, and when formed into particles by an air stream, the proportion of particles having an aerodynamic particle diameter of 5 ⁇ m or less is 10% or more.
- a lyophilized composition contains a poorly water-soluble drug, at least two kinds of amino acids, and a surfactant, and when formed into particles by an air stream, the proportion of particles having an aerodynamic particle diameter of 5 ⁇ m or less is 10% or more.
- C2 A lyophilized composition of a composition comprising a drug that is sparingly soluble in water, at least two types of amino acids, a surfactant, an alcohol, and water.
- C201 A freeze-dried composition of a composition comprising a poorly water-soluble drug, at least two types of amino acids, a surfactant, an alcohol, and water, A freeze-dried composition in which the proportion of particles having a particle size of 5 ⁇ m or less is 10% or more.
- C202 A freeze-dried composition of a composition comprising a poorly water-soluble drug, at least two types of amino acids, a surfactant, an alcohol, and water, A freeze-dried composition in which the proportion of particles having a mechanical particle size of 5 ⁇ m or less is 10% or more.
- C3 A freeze-dried composition comprising a poorly water-soluble drug, at least two amino acids selected from the following first group, second group and third group and a plurality of groups, and a surfactant: .
- -Group 1 Phenylalanine, tryptophan-Group 2: Isoleucine, leucine, valine-Group 3: Alanine, glycine
- C4 Drugs poorly soluble in water, and the following groups 1, 2, 3
- ⁇ Group 1 phenylalanine, tryptophan
- Group 2 isoleucine, leucine, valine
- Group 3 alanine, glycine
- the (C5) The (C1) to (C4), (C101), (C102), (C201), and (C1), wherein the water-insoluble drug is a compound having a differentiation-inducing action on alveolar epithelial stem cells.
- the compound having a differentiation-inducing action on alveolar epithelial stem cells is at least one selected from vitamin A, vitamin A derivatives, provitamin A, compounds acting on vitamin D receptors, and PI3 kinase inhibitors
- the freeze-dried composition according to (C5) which is a seed.
- the compound acting on the vitamin D receptor is vitamin D 2 and derivatives thereof, vitamin D 3 and derivatives thereof, vitamin D 4 and derivatives thereof, vitamin D 5 and derivatives thereof, vitamin D 6 and derivatives thereof, vitamins is at least one member selected from D 7 and its derivatives, freeze-dried composition according to the (C6).
- the PI3 kinase inhibitor is an agent that directly inhibits PI3 kinase, an agent that inhibits the PI3K-Akt pathway, an agent that inhibits the PI3K-BTK pathway, an agent that inhibits the PI3K-ITK pathway, PI3K-TAPP1 Agents that inhibit the pathway, agents that inhibit the PI3K-DAPP pathway, agents that inhibit the PI3K-GAB1 / 2 pathway, agents that inhibit the PI3K-Rac pathway, agents that inhibit the PI3K-Rho pathway, and inhibitors the PI3K-ARF pathway Agents that inhibit the PI3K-PDK1 pathway, agents that inhibit the PI3K-EEA1 pathway, agents that inhibit the PI3K-Rabenosyn5 pathway, agents that inhibit the PI3K-Rabip4 pathway, agents that inhibit the PI3K-FAB1 pathway, PI3K- an agent that inhibits the p40phox pathway, P Agent
- (C7) A step of preparing a first liquid by dissolving a poorly water-soluble drug in a solvent containing alcohol, the first liquid, at least two kinds of amino acids, a surfactant, water, A method for producing a lyophilized composition comprising the steps of preparing a second liquid by mixing and lyophilizing the second liquid.
- (C701) A step of preparing a first liquid by dissolving a poorly water-soluble drug in a solvent containing alcohol, and after mixing the first liquid and the surfactant, at least two kinds of A method for producing a lyophilized composition comprising a step of preparing a second liquid by mixing an amino acid and water, and a step of lyophilizing the second liquid.
- a step of preparing a first liquid by dissolving a poorly water-soluble drug in a solvent containing alcohol, the first liquid, and the following first group, second group, and third group Freezing comprising a step of preparing a second liquid by mixing at least two kinds of amino acids selected over a plurality of groups, a surfactant, and water, and a step of freeze-drying the second liquid A method for producing a dry composition.
- -Group 1 Phenylalanine, tryptophan-Group 2: Isoleucine, leucine, valine-Group 3: Alanine, glycine
- a first liquid is prepared by dissolving a poorly water-soluble drug in a solvent containing alcohol.
- the compound having a differentiation-inducing action on alveolar epithelial stem cells is at least one selected from vitamin A, vitamin A derivatives, provitamin A, compounds acting on vitamin D receptors, and PI3 kinase inhibitors
- the method for producing a lyophilized composition according to (C9), which is a seed which is a seed.
- the compound acting on the vitamin D receptor is vitamin D 2 and derivatives thereof, vitamin D 3 and derivatives thereof, vitamin D 4 and derivatives thereof, vitamin D 5 and derivatives thereof, vitamin D 6 and derivatives thereof, vitamins is at least one member selected from D 7 and its derivatives, method for producing a freeze-dried composition according to the (C10).
- the PI3 kinase inhibitor is an agent that directly inhibits PI3 kinase, an agent that inhibits the PI3K-Akt pathway, an agent that inhibits the PI3K-BTK pathway, an agent that inhibits the PI3K-ITK pathway, PI3K-TAPP1 Agents that inhibit the pathway, agents that inhibit the PI3K-DAPP pathway, agents that inhibit the PI3K-GAB1 / 2 pathway, agents that inhibit the PI3K-Rac pathway, agents that inhibit the PI3K-Rho pathway, and inhibitors the PI3K-ARF pathway Agents that inhibit the PI3K-PDK1 pathway, agents that inhibit the PI3K-EEA1 pathway, agents that inhibit the PI3K-Rabenosyn5 pathway, agents that inhibit the PI3K-Rabip4 pathway, agents that inhibit the PI3K-FAB1 pathway, PI3K- an agent that inhibits the p40phox pathway, P Production
- a differentiation inducer that acts on alveolar epithelial stem cells.
- the present invention also provides a pharmaceutical composition for inducing alveolar regeneration and a pharmaceutical composition for treating lung tissue damage.
- a freeze-dried composition containing a drug that is sparingly soluble in water, and is formed into particles having a particle size suitable for transpulmonary administration by airflow.
- a freeze-dried composition used for the production of a pharmaceutical composition for inducing regeneration of alveoli the freeze-dried composition that is granulated into particles having a particle size suitable for transpulmonary administration by air flow Things are provided.
- a pharmaceutical composition suitable for pulmonary administration which contains a drug hardly soluble in water.
- the present invention also provides a pharmaceutical composition that induces alveolar regeneration suitable for transpulmonary administration.
- 2 is a graph showing HE-stained images of a section of lung tissue treated with 1,25-dihydroxyvitamin D 3 and the average distance between alveolar walls in the COPD model mouse of Example B3.
- a numerical range indicated by using “to” indicates a range including the numerical values described before and after “to” as the minimum value and the maximum value, respectively.
- the term “process” is not limited to an independent process, and is included in this term if the intended purpose of the process is achieved even when it cannot be clearly distinguished from other processes.
- the “treatment” may be any improvement of symptoms, and the term also includes suppression of severity and reduction or alleviation of symptoms.
- “regeneration” is used in the meaning normally used in this technical field.
- composition containing PI3 kinase inhibitor PI3 kinase (phosphatidylinositol-3 kinase, PI3K) is an enzyme that phosphorylates the hydroxyl group (—OH group) at the 3-position of the inositol ring of inositol phospholipid.
- Inositol phospholipids are one of the components of eukaryotic cell membranes, and are catalyzed by kinases (phosphorylating enzymes) such as PI3K, so that phosphatidylinositol 3,4,5-triphosphate (PtdIns (3 , 4, 5) P3), and activation of protein kinase B (PKB) / Akt is associated with the control of cell survival, proliferation, differentiation, and cell death.
- kinases phosphorylating enzymes
- PtdIns phosphatidylinositol 3,4,5-triphosphate
- PBB protein kinase B
- a PI3K inhibitor is an agent that directly inhibits PI3 kinase and an agent that inhibits a downstream signal pathway of PI3K.
- the downstream signal pathway of PI3K is, for example, PI3K-Akt pathway, PI3K-BTK pathway, PI3K-ITK pathway, PI3K-TAPP pathway, PI3K-DAPP pathway, PI3K-GAB1 / 2 pathway, PI3K-Rac pathway, PI3K-Rho pathway , PI3K-ARF pathway, PI3K-PDK1 pathway, PI3K-EEA1 pathway, PI3K-Rabenosyn5 pathway, PI3K-Rabip4 pathway, PI3K-FAB1 pathway, PI3K-p40phox pathway, PI3K-SNX3 pathway, PI3K-SNX17 pathway, PI3K-SGK pathway It is.
- PI3K inhibitors have a differentiation-inducing action on alveolar epithelial stem cells.
- the present inventors have obtained a new finding that PI3K inhibitors induce differentiation of alveolar epithelial stem cells into type I and type II alveolar epithelial cells.
- PI3K inhibitor examples include the following compounds.
- Direct inhibitors of PI3K for example, Wortmannin, LY294002, AS605240, ZSTK474, PIK-75 Hydrochloride, IPI-145 (INK1197), GDC-0941, CAL-101 (Idelalisab, GS-1101), BEZ235 NVP-BEZ235, Dactolisib), BKM120 (NVP-BKM120, Buparlisb), GSK2636761, CZC24832, GDC-0032, VS-5684 (SB2343), TG100713, BYL719, CUDC-907, T ), BAY 80-6946 (Copanlist), PF-046 1502, PKI-402, CH5132799, GDC-0980 (RG7422), NU7441 (KU-57788), AS-252424, AS-604850, CAY10505, GSK212645 (GSK458), A66, PF-05212384 (PK
- a differentiation inducer that acts on alveolar epithelial stem cells, comprising a PI3K inhibitor as an active ingredient.
- the differentiation inducer differentiates alveolar epithelial stem cells into alveolar epithelial cells.
- the differentiation inducer contains at least one PI3K inhibitor as an active ingredient in a pharmaceutically acceptable medium.
- the medium include a solid medium (for example, gelatin and lactose) and a liquid medium (for example, alcohol, water, and physiological saline).
- the additive for preparation include excipients, disintegrants, binders, lubricants, surfactants, buffers, solubilizers, stabilizers, tonicity agents, and the like.
- a pharmaceutical composition for inducing alveolar regeneration comprising a PI3K inhibitor as an active ingredient.
- the pharmaceutical composition contains at least one PI3K inhibitor as an active ingredient in a pharmaceutically acceptable medium.
- the form of the pharmaceutical composition is not particularly limited, and is suitable for oral administration. Tablet, granule, powder, capsule, suspension, syrup, emulsion, limonade; ampoule for injection, freeze-dried powder for injection Agent; dry powder for transpulmonary administration; and the like.
- the medium include a solid medium (for example, gelatin and lactose) and a liquid medium (for example, alcohol, water, and physiological saline).
- the additive for preparation include excipients, disintegrants, binders, lubricants, surfactants, buffers, solubilizers, stabilizers, tonicity agents, and the like.
- a pharmaceutical composition for treating lung tissue damage comprising a PI3K inhibitor as an active ingredient.
- the pharmaceutical composition contains at least one PI3K inhibitor as an active ingredient in a pharmaceutically acceptable medium.
- the form of the pharmaceutical composition is not particularly limited, and is suitable for oral administration. Tablet, granule, powder, capsule, suspension, syrup, emulsion, limonade; ampoule for injection, freeze-dried powder for injection Agent; dry powder for transpulmonary administration; and the like.
- the medium include a solid medium (for example, gelatin and lactose) and a liquid medium (for example, alcohol, water, and physiological saline).
- the additive for preparation include excipients, disintegrants, binders, lubricants, surfactants, buffers, solubilizers, stabilizers, tonicity agents, and the like.
- a method for treating lung tissue damage comprising administering a pharmaceutical composition comprising a PI3K inhibitor as an active ingredient to a patient having damage to lung tissue.
- the pharmaceutical composition used for the treatment method is the pharmaceutical composition of [2] or the pharmaceutical composition of [3].
- patients having damage to lung tissue include chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, acute lung distress syndrome (ARDS), pulmonary fibrosis, lung cancer, Examples include interstitial pneumonia, pulmonary tuberculosis sequelae, and pneumoconiosis.
- COPD chronic obstructive pulmonary disease
- ARDS acute lung distress syndrome
- pulmonary fibrosis lung cancer
- Examples include interstitial pneumonia, pulmonary tuberculosis sequelae, and pneumoconiosis.
- the administration mode is not particularly limited, and various administration routes such as pulmonary administration, intravenous administration, and oral administration can be selected, and preferably pulmonary administration.
- the dose is selected depending on the type of disease; patient symptom, body weight, age; mode of administration; type of PI3K inhibitor;
- [5] to [8] and [5 '] to [8'] are provided.
- [5] to [8] and [5 ′] to [8 ′] correspond to [Freeze-dried composition], [Production method of freeze-dried composition], and [Pharmaceutical composition for transpulmonary administration] described later.
- a PI3K inhibitor as an active ingredient.
- the details of [5] to [8] and [5 ′] to [8 ′] are described later in [Freeze-dried composition], [Production method of freeze-dried composition], and [Pharmaceutical composition for transpulmonary administration]. It is the same.
- a lyophilized composition comprising a PI3K inhibitor, at least two types of amino acids, and a surfactant.
- a lyophilized composition comprising a PI3K inhibitor, at least two kinds of amino acids selected from the following first group, second group and third group and a plurality of groups, and a surfactant.
- ⁇ Group 1 phenylalanine, tryptophan
- Group 2 isoleucine, leucine, valine
- Group 3 alanine, glycine
- a lyophilized composition comprising a PI3K inhibitor, at least two amino acids, a surfactant, an alcohol, and water.
- Group 2 isoleucine, leucine, valine
- Group 3 alanine, glycine
- a method for producing a lyophilized composition comprising the steps of preparing a second liquid and lyophilizing the second liquid.
- [7 ′] A step of preparing a first liquid by dissolving a PI3K inhibitor in a solvent containing alcohol; the first liquid; a plurality of groups from the following first group, second group, and third group: A step of preparing a second liquid by mixing at least two kinds of amino acids selected over the two, a surfactant and water, and a step of freeze-drying the second liquid.
- a method for producing the composition ⁇ Group 1: phenylalanine, tryptophan ⁇ Group 2: isoleucine, leucine, valine ⁇ Group 3: alanine, glycine
- a pharmaceutical composition for transpulmonary administration wherein the freeze-dried composition according to [5] or [6] is granulated by airflow.
- [8 '] A pharmaceutical composition for transpulmonary administration, wherein the freeze-dried composition according to [5'] or [6 '] is granulated by an air stream.
- a method for transpulmonary administration of a pharmaceutical composition for pulmonary administration comprising the step of preparing the pharmaceutical composition for pulmonary administration by granulating with air impact.
- a differentiation inducer that acts on alveolar epithelial stem cells, comprising a PI3K inhibitor as an active ingredient; a pharmaceutical composition that induces alveolar regeneration
- a pharmaceutical composition for treating lung tissue damage a method for treating lung tissue damage; a lyophilized composition used in the manufacture of a pharmaceutical composition for treating lung tissue damage; suitable for transpulmonary administration by airflow;
- a freeze-dried composition that is granulated into particles having different particle sizes; a method for producing the freeze-dried composition; a pharmaceutical composition for treating lung tissue damage suitable for transpulmonary administration; a pharmaceutical composition for treating lung tissue damage A method of transpulmonary administration of the product.
- composition containing a compound that acts on vitamin D receptor 1,25-dihydroxyvitamin D 3 (calcitriol) is expressed in lung tissue of patients with chronic obstructive pulmonary disease (COPD) (Sundar IK. Et. Al., Biochem Biophys Res Commun. (2011) 406: 127-133.), But it has been reported to have differentiation-inducing action on alveolar epithelial stem cells. Absent. The present inventors have obtained a new finding that 1,25-dihydroxyvitamin D 3 induces differentiation of alveolar epithelial stem cells into type I and type II alveolar epithelial cells.
- COPD chronic obstructive pulmonary disease
- VDR acting compound a compound that acts on VDR (hereinafter referred to as “VDR acting compound”) is used for alveolar epithelial stem cells. It was considered to have a differentiation-inducing action.
- VDR acting compounds include compounds that bind directly to VDR, eg, VDR ligands, VDR agonists.
- VDR acting compounds include compounds that do not directly bind to VDR, such as anti-VDR ligand antibodies, compounds that promote signal transduction downstream of VDR, compounds that act on proteins constituting signal transduction pathways downstream of VDR, VDR Compounds that act as activators, compounds that inhibit VDR activator inhibitors are included.
- VDR ligands and agonists include, for example, vitamin D and derivatives thereof, and specifically include the following compounds.
- Vitamin D 2 and its derivatives eg ergosterol, ergocalciferol Vitamin D 3 and its derivatives: eg 7-dehydrocholesterol, previtamin D 3 , cholecalciferol, 25-hydroxycholecalciferol, 1,25 Dihydroxycholecalciferol (calcidiol), 1,25-dihydroxyvitamin D 3 (calcitriol), calcitronic acid Vitamin D 4 and its derivatives: eg dihydroergocalciferol Vitamin D 5 and its derivatives Vitamin D 6 And its derivatives Vitamin D 7 and its derivatives Vitamin D analogs: for example, dihydrotaxosterol, calcipotriol, tacalcitol, paricalcitol
- VDR acting compounds compounds acting on proteins constituting a signal transduction pathway downstream of VDR include, for example, RANKL (Receptor activator of NF-kappa B ligand) inhibitor and NF-kB (Nuclear factor-kappa B) inhibition.
- RANKL Receptor activator of NF-kappa B ligand
- NF-kB Nuclear factor-kappa B
- -RANKL inhibitor For example, WP9QY, Osteoprotegerin (OPG), anti-RANKL antibody (denosumab), RANKL siRNA, RANKL shRNA NF-kB inhibitors: for example, (5Z) -7-Oxoeaenol, (5Z) -Zeaenol, Andrographolide, Aurothiomalate, Capsaicin, (E) -Capsaicin, Evodiamine, anti-NF-kBsRNA, NF-kBsRNA, NF-kBsRNA, NF-kBsRNA
- the VDR active compound preferably 1,25-dihydroxyvitamin D 3.
- 1,25-dihydroxyvitamin D 3 shows the differentiation inducing effect on significantly alveolar epithelial stem cells at lower concentrations than ATRA.
- a differentiation inducer that acts on alveolar epithelial stem cells, comprising a VDR acting compound as an active ingredient.
- the differentiation inducer differentiates alveolar epithelial stem cells into alveolar epithelial cells.
- the differentiation inducer contains at least one VDR acting compound as an active ingredient in a pharmaceutically acceptable medium.
- the medium include a solid medium (for example, gelatin and lactose) and a liquid medium (for example, alcohol, water, and physiological saline).
- the additive for preparation include excipients, disintegrants, binders, lubricants, surfactants, buffers, solubilizers, stabilizers, tonicity agents, and the like.
- a pharmaceutical composition for inducing alveolar regeneration comprising a VDR acting compound as an active ingredient.
- the pharmaceutical composition contains at least one VDR acting compound as an active ingredient in a pharmaceutically acceptable medium.
- the form of the pharmaceutical composition is not particularly limited, and is suitable for oral administration. Tablet, granule, powder, capsule, suspension, syrup, emulsion, limonade; ampoule for injection, freeze-dried powder for injection Agent; dry powder for transpulmonary administration; and the like.
- the medium include a solid medium (for example, gelatin and lactose) and a liquid medium (for example, alcohol, water, and physiological saline).
- the additive for preparation include excipients, disintegrants, binders, lubricants, surfactants, buffers, solubilizers, stabilizers, tonicity agents, and the like.
- a pharmaceutical composition for treating lung tissue damage comprising a VDR acting compound as an active ingredient.
- the pharmaceutical composition contains at least one VDR acting compound as an active ingredient in a pharmaceutically acceptable medium.
- the form of the pharmaceutical composition is not particularly limited, and is suitable for oral administration. Tablet, granule, powder, capsule, suspension, syrup, emulsion, limonade; ampoule for injection, freeze-dried powder for injection Agent; dry powder for transpulmonary administration; and the like.
- the medium include a solid medium (for example, gelatin and lactose) and a liquid medium (for example, alcohol, water, and physiological saline).
- the additive for preparation include excipients, disintegrants, binders, lubricants, surfactants, buffers, solubilizers, stabilizers, tonicity agents, and the like.
- a method for treating lung tissue damage comprising administering a pharmaceutical composition comprising a VDR acting compound to a patient having damage to lung tissue.
- the pharmaceutical composition used for the treatment method is the pharmaceutical composition of [12] or the pharmaceutical composition of [13].
- patients having damage to lung tissue include chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, acute lung distress syndrome (ARDS), pulmonary fibrosis, lung cancer, Examples include interstitial pneumonia, pulmonary tuberculosis sequelae, and pneumoconiosis.
- the administration mode is not particularly limited, and various administration routes such as pulmonary administration, intravenous administration, and oral administration can be selected, and preferably pulmonary administration.
- the dosage is selected according to the type of disease; patient symptom, body weight, age; mode of administration; type of VDR acting compound;
- [15] to [18] and [15 '] to [18'] are provided.
- [15] to [18] and [15 ′] to [18 ′] correspond to [Freeze-dried composition], [Production method of freeze-dried composition], and [Pharmaceutical composition for transpulmonary administration] described later.
- a VDR acting compound as an active ingredient.
- the details of [15] to [18] and [15 ′] to [18 ′] are described later in [Freeze-dried composition], [Production method of freeze-dried composition], and [Pharmaceutical composition for transpulmonary administration]. It is the same.
- a lyophilized composition comprising a VDR acting compound, at least two types of amino acids, and a surfactant.
- a lyophilized composition comprising a VDR acting compound, at least two amino acids selected from the following first group, second group and third group and a plurality of amino acids, and a surfactant.
- ⁇ Group 1 phenylalanine, tryptophan
- Group 2 isoleucine, leucine, valine
- Group 3 alanine, glycine
- a lyophilized composition of a composition comprising a VDR acting compound, at least two types of amino acids, a surfactant, an alcohol, and water.
- Group 2 isoleucine, leucine, valine
- Group 3 alanine, glycine
- a method for producing a lyophilized composition comprising the steps of preparing a second liquid and lyophilizing the second liquid.
- [17 ′] A step of preparing a first liquid by dissolving a VDR acting compound in a solvent containing alcohol, the first liquid, and a plurality of groups from the following first group, second group, and third group
- a method for producing the composition ⁇ Group 1: phenylalanine, tryptophan ⁇
- Group 2 isoleucine, leucine, valine
- Group 3 alanine, glycine
- a pharmaceutical composition for transpulmonary administration wherein the freeze-dried composition according to [15] or [16] is granulated by air flow.
- [18 '] A pharmaceutical composition for transpulmonary administration, wherein the freeze-dried composition according to [15'] or [16 '] is granulated by air flow.
- [15], [16], [15 ′] or [16 ′] is filled into a transpulmonary administration device disclosed in, for example, US Pat. No. 7,735,485 B2 or US Pat. No. 4,822,709.
- the following [19] or [19 ′] invention is provided.
- a method for transpulmonary administration of a pharmaceutical composition for pulmonary administration comprising the step of preparing the pharmaceutical composition for pulmonary administration by granulating with air impact.
- a differentiation inducer that acts on alveolar epithelial stem cells using a VDR acting compound as an active ingredient; a pharmaceutical composition that induces alveolar regeneration
- a pharmaceutical composition for treating lung tissue damage a method for treating lung tissue damage; a lyophilized composition used in the manufacture of a pharmaceutical composition for treating lung tissue damage; suitable for transpulmonary administration by airflow;
- a freeze-dried composition that is granulated into particles having different particle sizes; a method for producing the freeze-dried composition; a pharmaceutical composition for treating lung tissue damage suitable for transpulmonary administration; a pharmaceutical composition for treating lung tissue damage A method of transpulmonary administration of the product.
- the lyophilized composition of the present invention is a lyophilized composition containing at least the following components.
- ⁇ Drugs poorly soluble in water hereinafter sometimes referred to as “active ingredients”) -At least 2 types of amino acids-Surfactant
- the lyophilized composition is a lyophilized composition of a composition (dispersion or lysate) containing at least the following components.
- ⁇ Slightly soluble drug ⁇ At least two kinds of amino acids ⁇ Surfactant ⁇ Alcohol ⁇ Water And when the freeze-dried composition is made into particles by air flow, the proportion of particles having a particle size of 5 ⁇ m or less is 10%.
- a freeze-dried composition containing a drug hardly soluble in water cannot be prepared, or it becomes a freeze-dried composition that is difficult to form particles even when subjected to airflow.
- a lyophilized composition that particles into unsuitable large particles When at least two kinds of amino acids are not used, a freeze-dried composition containing a drug hardly soluble in water cannot be prepared, or it becomes a freeze-dried composition that is difficult to form particles even when subjected to airflow. Or a lyophilized composition that particles into unsuitable large particles.
- the particle size is a geometric particle size or an aerodynamic particle size.
- the above-mentioned ratio is the ratio (volume%) of particles having a particle diameter of 5 ⁇ m or less with respect to all the particles with respect to the geometric particle diameter.
- the above ratio is the ratio (mass%) of the amount of drug contained in particles having a particle diameter of 5 ⁇ m or less with respect to the amount of drug contained in all particles (total amount of drug).
- the lyophilized composition of the present invention is preferably a lyophilized composition containing at least the following components.
- the lyophilized composition is preferably a lyophilized composition of a composition (dispersion or solution) containing at least the following components.
- -A poorly water-soluble drug-At least two amino acids selected from the following group 1, group 2 and group 3 across multiple groups-Group 1: phenylalanine, tryptophan-Group 2: isoleucine, Leucine, valine ⁇ Group 3: alanine, glycine ⁇ Surfactant ⁇ Alcohol ⁇ Water
- a specific type of amino acid selected in the above combination hereinafter also referred to as “specific amino acid”.
- the lyophilized composition of the present invention is a pre-preparation of a pharmaceutical composition for pulmonary administration (a lyophilized composition for the preparation of a pharmaceutical composition for pulmonary administration), and is granulated by air impact by inhalation of a patient, It produces particles with a geometric particle size of 5 ⁇ m or less.
- the ratio of the particles having a geometric particle diameter of 5 ⁇ m or less to the total particles generated from the freeze-dried composition of the present invention is preferably 10% or more, more preferably 15% or more, even more preferably on a volume basis. Is 20% or more, more preferably 25% or more, and particularly preferably 30% or more.
- the geometric particle diameter can be measured by, for example, a laser diffraction particle size distribution measuring apparatus.
- the lyophilized composition of the present invention is a pre-preparation of a pharmaceutical composition for pulmonary administration (a lyophilized composition for the preparation of a pharmaceutical composition for pulmonary administration). Particles having a particle size of 5 ⁇ m or less are generated.
- the ratio of the particles having an aerodynamic particle size of 5 ⁇ m or less to the total particles generated from the freeze-dried composition of the present invention is preferably 10% or more as the ratio (mass%) of the drug amount to the total drug amount. More preferably, it is 15% or more, more preferably 20% or more, still more preferably 25% or more, and particularly preferably 30% or more.
- the aerodynamic particle size can be measured by, for example, Multi-stage Liquid Impinger, Andersen Cascade Impactor, Next Generation Pharmaceutical Impactor and the like.
- the aerodynamic particle diameter of the particles needs to be a micro size of 5 ⁇ m or less. Since the aerodynamic particle size of the particles derived from the porous lyophilized composition is usually smaller than the geometric particle size, if the proportion of particles having a geometric particle size of 5 ⁇ m or less is within the above range, A sufficient proportion of particles of aerodynamic particle size suitable for pulmonary administration will be included.
- the lyophilized composition of the present invention is preferably a porous solid from the viewpoint of being easily atomized by airflow.
- the porous solid may be cracked, divided into several lumps, or may be partially broken as long as it can be granulated by an air stream.
- -Drugs poorly soluble in water- “Slightly soluble in water” for a drug means a compound that is 10 mg or less soluble in 1 ml of water at 20 ° C., and the amount of the compound is preferably 5 mg or less, more preferably 1 mg or less, More preferably, it is 0.5 mg or less, Most preferably, it is 0.1 mg or less.
- the poorly water-soluble drug include compounds having a differentiation-inducing action on alveolar epithelial stem cells.
- the compound having a differentiation-inducing action on alveolar epithelial stem cells is not particularly limited as long as it has a pharmacological activity that induces differentiation of alveolar epithelial stem cells (preferably human alveolar epithelial stem cells).
- alveolar epithelial stem cells when the compound is brought into contact with alveolar epithelial stem cells, at least one of type I alveolar epithelial cells and type II alveolar epithelial cells This can be confirmed by inducing the cells. Specifically, after culturing alveolar epithelial stem cells in a medium containing the compound, the cells were stained by immunostaining and observed with a fluorescence microscope, and AQP-5 (Aquaporin, a marker of type I alveolar epithelial cells) was observed.
- AQP-5 Amporin, a marker of type I alveolar epithelial cells
- SP-A Surfactant (apo) protein A, surfactant (apo) protein A
- apo surfactant (apo) protein A
- a marker of type II alveolar epithelial cells It can be confirmed by being.
- Examples of compounds having differentiation-inducing action on alveolar epithelial stem cells include vitamin A, vitamin A derivatives, provitamin A, compounds acting on vitamin D receptors, and PI3 kinase inhibitors. Include the following compounds.
- Vitamin A derivatives for example, retinoids such as all-trans-retinoic acid (ATRA. Tretinoin), retinol, retinal, and synthetic retinoids (eg tamibarotene).
- Provitamin A for example ⁇ -carotene, ⁇ -carotene Vitamin D 2 and its derivatives: eg ergosterol, ergocalciferol Vitamin D 3 and its derivatives: eg 7-dehydrocholesterol, previtamin D 3 , cholecalciferol, 25-hydroxycholecalciferol, 1,25-dihydroxycholecalciferol (calcidiol), 1,25-dihydroxyvitamin D 3 (calcitriol), calcitroic acid-vitamin D 4 and its derivatives: e.g., dihydro ergocalciferol Vita Emissions D 5 and derivatives thereof, vitamin D 6 and its derivatives, vitamin D 7 and its derivatives, vitamin D analogs: e.g., dihydro Taki sterol, calcipotriol, tacalcitol, direct inhibitor of paricalcitol-PI3K: for example, Wortmannin, LY294002, AS605240, ZSTK474,
- examples of poorly water-soluble drugs that can be expected to have a pharmacological effect on the lung include steroids (beclomethasone, fluticasone, budesonide, etc.) and herbal turmeric components (curcumin).
- the amount of the active ingredient contained in the lyophilized composition of the present invention is not particularly limited.
- the amount of the active ingredient contained in the lyophilized composition for a single dose is, for example, 20 mg or less, preferably 10 mg or less, more preferably 5 mg or less, still more preferably 2 mg or less, and particularly preferably 1 mg or less.
- the present invention uses at least two amino acids in combination.
- glycine Gly
- alanine Ala
- valine Val
- leucine Leu
- isoleucine Ile
- serine Ser
- threonine Thr
- aspartic acid Aspartic acid
- glutamic acid Glu
- Asn Asn
- glutamine Gln
- lysine Lys
- arginine Arg
- cysteine Cys
- methione Met
- phenylalanine Phe
- tyrosine Tyr
- tryptophan Trp
- Histidine His
- proline At least two types are selected from (Pro).
- the 20 amino acids other than glycine may be D-type or L-type, or a mixture of D-type and L-type.
- a preferable combination of at least two kinds of amino acids selected from the above amino acid group is that the lyophilized composition is easily formed into particles having a geometric particle diameter of 5 ⁇ m or less, and Phe or Trp / Ile, Leu, Val, At least one selected from Ala and Gly; at least one selected from Ile, Leu and Val / at least one selected from Ala and Gly; Among these, at least one combination selected from Phe or Trp / Ile, Leu and Val is more preferable, and a combination of Phe / Ile, Phe / Leu, Phe / Val and Trp / Ile is particularly preferable.
- the total content of amino acids in the lyophilized composition of the present invention is not particularly limited, but is, for example, 0.001% by mass or more and less than 100% by mass, preferably 0.01% by mass or more and less than 100% by mass, more Preferably they are 0.1 mass% or more and less than 100 mass%, More preferably, they are 1 mass% or more and less than 100 mass%, Especially preferably, they are 10 mass% or more and less than 100% mass.
- the present invention it is preferable to use at least two kinds of amino acids selected from the following first group, second group and third group as a plurality of groups as at least two kinds of amino acids.
- the combination of a plurality of groups is a combination of the first group and the second group, a combination of the first group and the third group, a combination of the second group and the third group, and a combination of the first group, the second group and the third group. Any combination may be used.
- First group phenylalanine (Phe), tryptophan (Trp)
- Second group isoleucine (Ile), leucine (Leu), valine (Val)
- Group 3 alanine (Ala), glycine (Gly)
- the amino acids other than glycine may be D-type or L-type, or a mixture of D-type and L-type.
- At least one of the two types is preferably an amino acid selected from the first group in that the freeze-dried composition is easily granulated into particles having a geometric particle size of 5 ⁇ m or less, that is, Phe or Trp Is preferred.
- a preferred combination of at least two types of amino acids is at least selected from Phe or Trp / Ile, Leu, Val, Ala and Gly in that the lyophilized composition is easily granulated into particles having a geometric particle size of 5 ⁇ m or less.
- the total content of the specific amino acids in the lyophilized composition of the present invention is not particularly limited, but is, for example, 0.001% by mass or more and less than 100% by mass, preferably 0.01% by mass or more and less than 100% by mass, More preferably, they are 0.1 mass% or more and less than 100 mass%, More preferably, they are 1 mass% or more and less than 100 mass%, Especially preferably, they are 10 mass% or more and less than 100% mass.
- the freeze-dried composition of the present invention may contain an amino acid other than the specific amino acid when at least two kinds of amino acids are the specific amino acid.
- a drug that is sparingly soluble in water is used by dissolving it in a solvent containing alcohol. Since alcohol volatilizes by lyophilization, it is usually not included in lyophilized compositions. Examples of the alcohol include ethanol, methanol, isopropyl alcohol, ethylene glycol, and the like, and preferably ethanol. These may be used alone or in combination of two or more.
- any anionic surfactant, cationic surfactant, or nonionic surfactant can be used as long as it is a surfactant that is usually used in pharmaceuticals.
- nonionic surfactants such as polyoxyethylene sorbitan fatty acid ester (for example, Tween surfactant) and sorbitan trioleate are exemplified.
- surfactant examples include sucrose fatty acid ester, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, polyoxyethylene hydrogenated castor oil 140, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60.
- the composition (dispersion or solution) subjected to freeze-drying is a liquid containing water as a main solvent. Since all or most of the water is lost by the lyophilization process, the water is not included in the lyophilized composition, or a small amount, if any, is included.
- the lyophilized composition of the present invention may contain other components in addition to the above components as long as the final preparation (pharmaceutical composition for pulmonary administration) does not affect the human body.
- Other components include stabilization of active ingredients in the composition (dispersion or solution) to be lyophilized, stabilization of active ingredients after lyophilization, prevention of adsorption of active ingredients to containers, etc.
- Pharmaceutical additives commonly used in the art for the purpose excipients, disintegrants, binders, lubricants, surfactants, buffers, solubilizers, stabilizers, tonicity agents, etc. May be used.
- the lyophilized composition of the present invention may contain a carrier other than amino acids.
- carriers other than amino acids monosaccharides such as glucose; disaccharides such as sucrose, maltose, lactose and trehalose; oligosaccharides such as cyclodextrin; polysaccharides such as dextran 40 and pullulan; fatty acid sodium such as sodium caprate; Is mentioned. These may be used alone or in combination of two or more.
- the amount of these carriers to be blended is not particularly limited as long as the lyophilized composition is granulated by an air stream. As a guide, it is blended so that the proportion of the lyophilized composition is 0.1% by mass or more and less than 100% by mass.
- the method for producing a freeze-dried composition of the present invention includes freeze-drying a composition (dispersion or solution) containing at least the following components. ⁇ Slightly soluble drugs ⁇ At least two amino acids ⁇ Surfactant ⁇ Alcohol ⁇ Water
- the method for producing a freeze-dried composition of the present invention preferably includes freeze-drying a composition (dispersion or solution) containing at least the following components.
- a composition (dispersion or solution) containing at least the following components.
- Group 3 Alanine, glycine ⁇ Surfactant ⁇ Alcohol ⁇ Water
- the method for producing a lyophilized composition of the present invention preferably includes the following steps (A) to (C). According to the production method including the steps (A) to (C), it is possible to prepare a liquid (dispersion or solution) containing water as a main solvent in which the active ingredient is well dispersed or dissolved. A porous lyophilized composition can be produced that is granulated into a size suitable for transpulmonary administration by airflow.
- the step (B) is preferably the following step (B ′).
- a second liquid by mixing the following:-Group 1: phenylalanine, tryptophan-Group 2: isoleucine, leucine, valine-Group 3: alanine, glycine
- Step (A) is a step of preparing a first liquid in which a poorly water-soluble drug (active ingredient) is dissolved in a solvent containing alcohol.
- the solvent containing alcohol may be a solvent of alcohol alone or an aqueous alcohol solution.
- the alcohol include ethanol, methanol, isopropyl alcohol, ethylene glycol, and the like, and preferably ethanol.
- the alcohol concentration of the solvent containing alcohol is not particularly limited as long as the active ingredient can be dissolved. However, since it is desirable that the second liquid to be subjected to freeze-drying has a low alcohol concentration in terms of easy freeze-drying, the alcohol concentration of the solvent containing alcohol may be adjusted from the above viewpoint.
- the solvent containing alcohol may contain an organic solvent other than alcohol as a solubilizer, as long as the final preparation (pharmaceutical composition for pulmonary administration) does not affect the human body.
- organic solvent include acetone.
- step (B) preferably step (B ′)
- the first liquid in which the active ingredient is dissolved, at least two kinds of amino acids (preferably specific amino acids), a surfactant, and water are mixed.
- This is a step of preparing a second liquid (dispersion or solution). Since the first liquid usually has an alcohol concentration that is so high that it is difficult to freeze-dry, it is necessary to add water to lower the alcohol concentration to adjust the alcohol concentration to be easily freeze-dried.
- Step (B) is a step of adjusting the alcohol concentration by adding water while favorably dispersing or dissolving the active ingredient with at least two types of amino acids (preferably specific amino acids) and a surfactant.
- the order of mixing the first liquid, the amino acid and the surfactant is not limited, but the dispersibility or solubility of the active ingredient in the second liquid is better. And the aspect which mixes a 1st liquid and surfactant and mixes an amino acid after that is preferable. Specifically, a surfactant is added to the first liquid to prepare a solution containing the active ingredient and the surfactant, and this solution is mixed with an amino acid-containing solution in which an amino acid is dissolved or dispersed in water. Embodiments are preferred.
- the concentration of the active ingredient in the second liquid is, for example, 0.001 mg / mL to 1000 mg / mL, preferably 0.001 mg / mL to 100 mg / mL, more preferably It is 0.001 mg / mL to 10 mg / mL, more preferably 0.001 mg / mL to 1 mg / mL, and particularly preferably 0.001 mg / mL to 0.1 mg / mL.
- the total amount of amino acids relative to the amount of the active ingredient is, for example, 50 parts by weight to 80000 parts by weight, preferably 100 parts by weight to 40000 parts by weight, when the amount of the active ingredient is 100 parts by weight.
- the amount is preferably 200 parts by weight to 20000 parts by weight, more preferably 400 parts by weight to 10,000 parts by weight, and particularly preferably 800 parts by weight to 8000 parts by weight.
- the total concentration of amino acids in the second liquid is not particularly limited. For example, what is necessary is just to adjust according to the quantity and kind of active ingredient, for example, 0.001 mg / mL or more, 0.01 mg / mL or more, and 0.1 mg / mL or more.
- the total concentration of the amino acids in the second liquid is preferably 10 mg / mL or less, more preferably 8 mg / mL or less, and even more preferably 4 mg in that the lyophilized composition is well porous and easily atomized by airflow. / ML or less, particularly preferably 2 mg / mL or less.
- the mass ratio of amino acids contained in the second liquid is, for example, in the range of 10:90 to 90:10, preferably 20:80. 80:20, more preferably 30:70 to 70:30, and still more preferably 40:60 to 60:40.
- the concentration of the surfactant in the second liquid is, for example, 0.0001% by mass to 1% by mass, preferably 0.001% by mass to 0.5% by mass, More preferably, it is 0.005% by mass to 0.5% by mass, still more preferably 0.005% by mass to 0.3% by mass, and particularly preferably 0.005% by mass to 0.1% by mass.
- the alcohol concentration of the second liquid is preferably 0.1% by mass to 20% by mass, more preferably 0.1% by mass to 10% by mass, still more preferably 0.5% by mass to 10% by mass, particularly preferably. 0.5 mass% to 5 mass%.
- step (B) formulation additives (excipients, disintegrants, binders, lubricants, surfactants, buffers, solubilizers, stabilizers, tonicity agents, etc.) are further mixed. May be. A carrier other than amino acids may be mixed.
- Step (C) is a step of freeze-drying the second liquid obtained in step (B).
- the method for freeze-drying the second liquid is not particularly limited, and may be, for example, a freeze-drying method that is conventionally applied to the production of a conventionally known freeze-dried drug (for example, an injection that is dissolved at the time of use).
- the pharmaceutical composition for transpulmonary administration of the present invention is a powdery pharmaceutical composition obtained by granulating the lyophilized composition of the present invention into an air stream.
- One aspect of the pharmaceutical composition for pulmonary administration of the present invention comprises a compound having an action of inducing differentiation of alveolar epithelial stem cells (preferably human alveolar epithelial stem cells) as an active ingredient.
- the pharmaceutical composition for pulmonary administration of the present invention contains a compound having a differentiation-inducing action on alveolar epithelial stem cells, it can be used as a therapeutic agent for a disease exhibiting lung tissue damage.
- the disease include chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, acute lung distress syndrome (ARDS), pulmonary fibrosis, lung cancer, interstitial pneumonia, pulmonary tuberculosis. Examples include sequelae and pneumoconiosis. Therefore, according to the pharmaceutical composition for transpulmonary administration of the present invention, a method for treating a disease exhibiting lung tissue damage is provided.
- the therapeutic method is a method for treating pulmonary tissue damage, comprising pulmonary administration of the pharmaceutical composition for pulmonary administration of the present invention to a patient having damage to pulmonary tissue (for example, a patient having the above-mentioned diseases).
- the dosage of the pharmaceutical composition for pulmonary administration of the present invention is selected according to the type of disease; patient symptom, body weight, age; type of compound contained as an active ingredient, and the like.
- the pharmaceutical composition for transpulmonary administration of the present invention is prepared by pulverizing a freeze-dried composition for preparation with an air stream.
- the flow rate of the air flow is 5 L / min to 300 L / min, more preferably 10 L / min to 200 L / min, still more preferably 10 L / min to 150 L / min, and particularly preferably 10 L / min to 100 L / min.
- the flow rate of the airflow is 1 m / sec to 300 m / sec, more preferably 2 m / sec to 250 m / sec, still more preferably 5 m / sec to 200 m / sec, and particularly preferably 10 m / sec to 150 m / sec.
- the pharmaceutical composition for pulmonary administration of the present invention can be formed into particles by the lyophilized composition for its preparation by a relatively low velocity and flow rate of air flow, and therefore, as an administration mode, for example, US Pat. No. 7,735,485 B2 or Patent
- the transpulmonary administration system disclosed in Japanese Patent No. 4822709 can be employed. That is, if the freeze-dried composition is provided together with the device for transpulmonary administration disclosed in the above document, the user of the device attaches a vial of the freeze-dried composition to the device at the time of use, and the freeze-dried composition is inhaled by the patient's inspiration.
- the product becomes particles suitable for transpulmonary administration and can be taken as it is by inhalation.
- the lyophilized composition of the present invention is provided together with the above-mentioned device for pulmonary administration, for example, one embodiment of a method for pulmonary administration of the pharmaceutical composition for pulmonary administration is provided.
- the pulmonary administration method when the patient inhales the pharmaceutical composition for pulmonary administration of the present invention, the patient applies airflow to the freeze-dried composition of the present invention to form particles that are suitable for pulmonary administration. The process of including.
- the proportion of particles having a particle size of 5 ⁇ m or less in the total particles is preferably 10% or more, more preferably 15% or more, still more preferably 20% or more, More preferably, it is 25% or more, and particularly preferably 30% or more.
- the particle diameter means a geometric particle diameter or an aerodynamic particle diameter.
- the above-mentioned ratio is the ratio (volume%) of particles having a particle diameter of 5 ⁇ m or less with respect to all the particles with respect to the geometric particle diameter.
- the above ratio is the ratio (mass%) of the amount of drug contained in particles having a particle diameter of 5 ⁇ m or less with respect to the amount of drug contained in all particles (total amount of drug).
- the proportion (volume%) of particles having a geometric particle size of 5 ⁇ m or less in the total particles is preferably 10% or more, more preferably 15% or more, and further Preferably it is 20% or more, More preferably, it is 25% or more, Most preferably, it is 30% or more.
- the ratio (mass%) of the drug amount contained in particles having an aerodynamic particle size of 5 ⁇ m or less with respect to the total drug amount is preferably 10% or more, more preferably. It is 15% or more, more preferably 20% or more, further preferably 25% or more, and particularly preferably 30% or more.
- the particles in order for particles administered transpulmonarily to reach and deposit in the lung, the particles must have an aerodynamic particle size of 5 ⁇ m or less. Since the aerodynamic particle size of the particles derived from the porous lyophilized composition is usually smaller than the geometric particle size, if the proportion of particles having a geometric particle size of 5 ⁇ m or less is within the above range, A sufficient proportion of particles of aerodynamic particle size suitable for pulmonary administration will be included.
- CD90 is a marker for alveolar epithelial stem cells
- AQP-5 is a marker for type I alveolar epithelial cells
- SP-A is a marker for type II alveolar epithelial cells.
- Reference Example 1 Verification of differentiation-inducing action of ATRA on human alveolar epithelial stem cells
- Human alveolar epithelial stem cells used in Reference Example 1 were derived from human lung alveolar epithelial stem cells (Fujino N, at. Al. Am. J) derived from patients with lung disease (biopsy in lung cancer or COPD or surgical tissue removed during surgery). Respir. Cell Mol. Biol., 46, 422-430 (2012)).
- the human alveolar epithelial stem cells are obtained by sterilizing the culture supernatant of mouse fetal fibroblasts cultured in DMEM medium containing 10% bovine serum (FBS) and 1% 50-fold diluted MEM (Amino Acids Solution). Using the prepared culture solution, it was cultured and maintained in a 37 ° C./5% CO 2 environment.
- FBS bovine serum
- MEM Amo Acids Solution
- All-trans retinoic acid is exposed to human alveolar epithelial stem cells (1 ⁇ 10 1-4 cells / cm 2 ) in the culture at a concentration of 0 ⁇ M, 0.01 ⁇ M, 0.1 ⁇ M, 1 ⁇ M, or 10 ⁇ M.
- the culture was stationary for 5 days in a 37 ° C./5% CO 2 environment.
- the cultured cells were washed with PBS (Phosphate Buffered Saline) and fixed with a 4% paraformaldehyde-PBS solution.
- PBS Phosphate Buffered Saline
- goat anti-human CD90 antibody SantaSCruz
- goat anti-human AQP-5 antibody Santa ⁇ Cruz
- goat anti-human SP-A antibody Santa ⁇ Cruz
- Anti-goat antibody manufactured by Santa Cruz
- Example A1 Verification of differentiation-inducing effect of PI3K inhibitor on human alveolar epithelial stem cells
- the human alveolar epithelial stem cells used in Example A1 are human alveolar epithelial stem cells (Fujino N, at. Al. Am. J) derived from patients with lung diseases (biopsy in lung cancer or COPD, or excised tissues at the time of surgery). Respir. Cell Mol. Biol., 46, 422-430 (2012)).
- the human alveolar epithelial stem cells are obtained by sterilizing the culture supernatant of mouse fetal fibroblasts cultured in DMEM medium containing 10% bovine serum (FBS) and 1% 50-fold diluted MEM (Amino Acids Solution). Using the prepared culture solution, it was cultured and maintained in a 37 ° C./5% CO 2 environment.
- FBS bovine serum
- MEM Amino Acids Solution
- Human alveolar epithelial stem cells (1 ⁇ 10 1 to 4 cells / cm 2 ) in the culture medium are mixed with PI3K inhibitor Wortmannin at a concentration of 0 ⁇ M, 0.01 ⁇ M, 0.1 ⁇ M, 1 ⁇ M, or 10 ⁇ M. After exposure, the cells were statically cultured in a 37 ° C./5% CO 2 environment for 5 days.
- the cultured cells were washed with PBS (Phosphate Buffered Saline) and fixed with a 4% paraformaldehyde-PBS solution.
- PBS Phosphate Buffered Saline
- goat anti-human CD90 antibody SantaSCruz
- goat anti-human AQP-5 antibody Santa ⁇ Cruz
- goat anti-human SP-A antibody Santa ⁇ Cruz
- Anti-goat antibody manufactured by Santa Cruz
- the PI3K inhibitor showed a strong differentiation-inducing action on alveolar epithelial stem cells at a lower concentration than ATRA.
- the concentrations of 0.1 ⁇ M are compared, the PI3K inhibitor has a differentiation-inducing action on type I alveolar epithelial cells that is 3 times or more of ATRA, and has a differentiation-inducing action on type II alveolar epithelial cells that is twice or more. showed that.
- Example A2 Verification of effect of PI3K inhibitor on COPD animal model
- a 6-week-old ICR mouse male was administered pulmonary elastase (7.5 U, manufactured by Wako) suspended in 50 ⁇ L of PBS twice a week with a sonde for one week to prepare an emphysema model. Subsequently, wortmannin was transpulmonary administered twice a week for 3 weeks at a dose of 10 ⁇ g / kg each time with a sonde. Twenty-one days after the first administration of wortmannin, both lungs were removed, tissues were fixed with paraformaldehyde, sections were prepared with cryostat, and hematoxylin / eosin staining (HE staining) was performed.
- pulmonary elastase 7.5 U, manufactured by Wako
- wortmannin was transpulmonary administered twice a week for 3 weeks at a dose of 10 ⁇ g / kg each time with a sonde. Twenty-one days after the first administration of wortmannin, both lungs were removed, tissues were fixed with paraformalde
- the method draws a number of random lines, places them on the alveolar image, finds the sum of the lengths of the sections separated by the alveolar walls of each random line, and divides this by the total number of broken lines. It is required by doing.
- the number of divisions by the alveolar septum per visual field is set to 200 mm or more, this is measured in 30 visual fields (6 cross sections x 5 visual fields) per individual, the average is calculated, and the average alveolar wall distance of each mouse is obtained, The average of each group (6 individuals) was calculated, and statistical analysis was performed by t-test. The results are shown in Table 3 and FIG.
- Human alveolar epithelial stem cells used in Examples B1 and B2 are patients with lung disease (extracted tissue at the time of biopsy or surgery in lung cancer or COPD) Derived from human alveolar epithelial stem cells (Fujino N, at. Al. Am. J. Respir. Cell Mol. Biol., 46, 422-430 (2012)).
- the human alveolar epithelial stem cells are obtained by sterilizing the culture supernatant of mouse fetal fibroblasts cultured in DMEM medium containing 10% bovine serum (FBS) and 1% 50-fold diluted MEM (Amino Acids Solution). Using the prepared culture solution, it was cultured and maintained in a 37 ° C./5% CO 2 environment.
- Example B1 Verification of differentiation-inducing action of 1,25-dihydroxyvitamin D 3 on human alveolar epithelial stem cells (1)
- 1,25-dihydroxyvitamin D 3 is exposed to human alveolar epithelial stem cells (1 ⁇ 10 1 to 4 cells / cm 2 ) in the culture at a concentration of 0 ⁇ M, 0.01 ⁇ M, 0.1 ⁇ M, 1 ⁇ M or 10 ⁇ M. Then, static culture was performed in a 37 ° C./5% CO 2 environment for 5 days.
- the cultured cells were washed with PBS (Phosphate Buffered Saline) and fixed with a 4% paraformaldehyde-PBS solution.
- PBS Phosphate Buffered Saline
- goat anti-human CD90 antibody SantaSCruz
- goat anti-human AQP-5 antibody Santa ⁇ Cruz
- goat anti-human SP-A antibody Santa ⁇ Cruz
- Anti-goat antibody manufactured by Santa Cruz
- Example B1 is compared with the reference example 1, 1,25-dihydroxyvitamin D 3 is at a lower concentration than ATRA, it showed strong differentiation-inducing effect on alveolar epithelial stem cells.
- 1,25-dihydroxyvitamin D 3 has a differentiation-inducing action on type I alveolar epithelial cells that is 7 times or more of ATRA, and more than 3 times type II alveolar epithelial cells. Showed differentiation-inducing action.
- Example B2 Verification of differentiation-inducing action of 1,25-dihydroxyvitamin D 3 on human alveolar epithelial stem cells (2)
- An experiment similar to Example B1 was conducted, except that the concentration of 1,25-dihydroxyvitamin D 3 was 10 ⁇ M and the culture days were 0 days, 1 day, 2 days, 4 days or 6 days. The results are shown in Table 5.
- the cells were fixed with a 4% paraformaldehyde-PBS solution immediately after exposure to 1,25-dihydroxyvitamin D 3 and washed with PBS.
- Example B3 1,25- Verification of effect on COPD animal model dihydroxyvitamin D 3] Experiments were conducted to confirm the effects of 1,25-dihydroxyvitamin D 3 using COPD model mice (elastase-induced emphysema mice).
- a 6-week-old ICR mouse male was subjected to pulmonary administration of elastase (7.5 U, manufactured by Wako) suspended in 50 ⁇ L of PBS twice a week with a sonde for one week to prepare an emphysema model. Subsequently, 1,25-dihydroxyvitamin D 3 twice a week for three weeks, at a dose of each time 10 [mu] g / kg, and transpulmonary administration at sonde.
- elastase 7.5 U, manufactured by Wako
- the method draws a number of random lines, places them on the alveolar image, finds the sum of the lengths of the sections separated by the alveolar walls of each random line, and divides this by the total number of broken lines. It is required by doing.
- the number of divisions by the alveolar septum per visual field is set to 200 mm or more, this is measured in 30 visual fields (6 cross sections x 5 visual fields) per individual, the average is calculated, and the average alveolar wall distance of each mouse is obtained, The average of each group (6 individuals) was calculated, and statistical analysis was performed by t-test. The results are shown in Table 6 and FIG.
- the control group (without administration of 1,25-dihydroxyvitamin D 3 ) has a markedly expanded alveolar space and experimental pathological COPD lesions (significant emphysema) caused by elastase. It was confirmed.
- 1,25-dihydroxyvitamin D 3 administration group the distance between the average alveolar wall were significantly lower. Low distances between the average alveolar wall shows that the alveoli is played, the alveoli is reproduced by the administration 1,25-dihydroxyvitamin D 3, the 1,25-dihydroxyvitamin D 3 It has been found to be effective in treating lung tissue damage.
- [C] Lyophilized composition The amino acids used in Examples C1 to C4 are in the L form other than glycine.
- Example C1 Preparation of lyophilized composition containing ATRA (1)
- Preparation of lyophilized composition 4 mg of ATRA was dissolved in 1 mL of ethanol, and 20 ⁇ L of Tween 20 was added as a surfactant to prepare an ATRA solution.
- amino acid aqueous solutions of Phe, Leu, Ile and Val were prepared. The amino acid concentration of the aqueous amino acid solution was 6 mg / mL for Phe, and 2.4 mg / mL for Leu, Ile, and Val.
- an aqueous amino acid solution was added to the ATRA solution so that the final amount of amino acid was as shown in Table 7, and the amount of the aqueous solution was adjusted with water to prepare a dispersion in which ATRA was dispersed.
- the final concentration of ethanol in each dispersion was 5% by weight.
- Table 7 shows the final amounts of the active ingredients and amino acids of each dispersion and the final concentration of the surfactant.
- the liquid volume of 1 vial dispersion is 0.5 mL.
- 0.5 mL of this dispersion is put into a glass container (vial) having a body diameter of 18 mm and a volume of 2 mL, and is rapidly frozen under acetone-dry ice. Thereafter, a shelf-like freeze dryer (Freezone Triad, manufactured by LABCONCO) is used. And lyophilized to obtain a lyophilized composition.
- a shelf-like freeze dryer Freezone Triad, manufactured by LABCONCO
- the appearance of the lyophilized composition was evaluated according to the following evaluation criteria. The results are shown in Table 7.
- 1 The freeze-dried composition is not completed or is extremely small.
- Example C2 Preparation of lyophilized composition containing ATRA (2)
- Example C2-1 and Comparative Example C2-1 1 mg of ATRA was dissolved in 0.25 mL of ethanol, and 2.5 ⁇ L of Tween 80 was added as a surfactant to prepare an ATRA solution.
- amino acid aqueous solutions of Phe and Leu were prepared. The amino acid concentration of the aqueous amino acid solution was 4 mg / mL for Phe and 16 mg / mL for Leu. Then, an aqueous amino acid solution was added to the ATRA solution so that the final amount of amino acid was as shown in Table 8, and the amount of the aqueous solution was adjusted with water to prepare a dispersion in which ATRA was dispersed.
- Example C2-2 1 mg of ATRA was dissolved in 0.25 mL of ethanol, and 5 ⁇ L of Tween 80 was added as a surfactant to prepare an ATRA solution.
- amino acid aqueous solutions of Phe and Leu were prepared.
- the amino acid concentration of the aqueous amino acid solution was 4 mg / mL for Phe and 16 mg / mL for Leu.
- an aqueous amino acid solution was added to the ATRA solution so that the final amount of amino acid was as shown in Table 8, and the amount of the aqueous solution was adjusted with water to prepare a dispersion in which ATRA was dispersed.
- Example C2-3 and Comparative Example C2-3 5 mg of ATRA was dissolved in 1.25 mL of ethanol, and 25 ⁇ L of Tween 80 was added as a surfactant to prepare an ATRA solution.
- amino acid aqueous solutions of Phe and Gly were prepared.
- the amino acid concentration of the aqueous amino acid solution was 8 mg / mL for Phe and 8 mg / mL for Gly.
- an aqueous amino acid solution was added to the ATRA solution so that the final amount of amino acid was as shown in Table 8, and the amount of the aqueous solution was adjusted with water to prepare a dispersion in which ATRA was dispersed.
- the final concentration of ethanol in each dispersion was 5% by mass.
- Table 8 shows the final amounts of the active ingredients and amino acids of each dispersion and the final concentration of the surfactant.
- the liquid volume of 1 vial dispersion is 0.5 mL.
- Example C3 Preparation of lyophilized composition containing ATRA (3)
- 5 mg of ATRA was dissolved in 1.25 mL of ethanol, and 25 ⁇ L of Tween 80 was added as a surfactant to prepare an ATRA solution.
- amino acid aqueous solutions of amino acids described in Table 9 were prepared. The amino acid concentration of the aqueous amino acid solution was 8 mg / mL.
- an aqueous amino acid solution was added to the ATRA solution so that the final amount of amino acid was as shown in Table 9, and the liquid volume was adjusted with water to prepare a dispersion in which ATRA was dispersed.
- the final concentration of ethanol in each dispersion was 5% by weight.
- Table 9 shows the final amounts of the active ingredients and amino acids and the final concentration of the surfactant in each dispersion.
- the liquid volume of 1 vial dispersion is 0.5 mL.
- Example C4 1,25- Preparation of lyophilized compositions that comprise the dihydroxyvitamin D 3] 0.1 mg of 1,25-dihydroxyvitamin D 3 was dissolved in 0.25 mL of ethanol, and 5 ⁇ L of Tween 20 was added as a surfactant and dissolved. Separately, amino acid aqueous solutions of Phe and Leu were prepared. The amino acid concentration of the aqueous amino acid solution was 4 mg / mL for Phe and 16 mg / mL for Leu.
- an aqueous amino acid solution is added to the 1,25-dihydroxyvitamin D 3 solution so that the final amount of the amino acid is as shown in Table 10, and the liquid volume is adjusted with water, and 1,25-dihydroxyvitamin D 3 is added.
- a solution (5 mL) in which was dissolved was prepared.
- the final concentration of ethanol in each dispersion was 5% by weight.
- Table 10 shows the final amounts of active ingredients and amino acids and the final concentration of the surfactant in each dispersion.
- the liquid volume of 1 vial dispersion is 0.5 mL.
- Example C1 From this dispersion, a freeze-dried composition was obtained in the same manner as in Example C1, and the appearance and particle formation were evaluated. The results are shown in Table 10.
- Example C4 As is apparent from Table 10, the freeze-dried composition of Example C4 was granulated by an air flow, and became a powdered drug in which particles having a particle diameter of 5 ⁇ m or less accounted for 20% or more. This result shows that a drug suitable for pulmonary administration is prepared from the lyophilized composition of the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne une composition pharmaceutique comprenant un inhibiteur de kinase PI3 en tant qu'ingrédient actif. La présente invention concerne également une composition pharmaceutique comprenant un composé qui agit sur un récepteur de vitamine D en tant qu'ingrédient actif. La présente invention concerne également une composition lyophilisée d'une composition comprenant un médicament à faible solubilité dans l'eau, au moins deux types d'acides aminés, un tensioactif, de l'alcool et de l'eau.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014553227A JPWO2014098232A1 (ja) | 2012-12-21 | 2013-12-20 | Pi3キナーゼ阻害剤を含む医薬組成物、ビタミンd受容体に作用する化合物を含む医薬組成物、凍結乾燥組成物、凍結乾燥組成物の製造方法、及び経肺投与用医薬組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012280070 | 2012-12-21 | ||
JP2012-280070 | 2012-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014098232A1 true WO2014098232A1 (fr) | 2014-06-26 |
Family
ID=50978546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/084310 WO2014098232A1 (fr) | 2012-12-21 | 2013-12-20 | Composition pharmaceutique comprenant un inhibiteur de kinase pi3, composition pharmaceutique comprenant un composé qui agit sur un récepteur de vitamine d, composition lyophilisée, procédé de production de composition lyophilisée et composition pharmaceutique destinée à être administrée par voie transpulmonaire |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2014098232A1 (fr) |
WO (1) | WO2014098232A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019031447A (ja) * | 2017-08-04 | 2019-02-28 | タンデム カンパニー,リミテッド | 新規な組換えエキソソーム及びその用途 |
CN115840004A (zh) * | 2022-08-08 | 2023-03-24 | 中国医学科学院基础医学研究所 | 一种检测视黄醇代谢产物的试剂在制备诊断和/或治疗尘肺病工具中的应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003526679A (ja) * | 2000-03-13 | 2003-09-09 | コリア インスティチュート オブ サイエンス アンド テクノロジー | 各種物質の可溶化用組成物と剤形及びそれらの製造方法 |
WO2006038552A1 (fr) * | 2004-10-01 | 2006-04-13 | Eisai R & D Management Co., Ltd. | Composition contenant de fines particules et procédé de fabrication de ladite composition |
JP2006521813A (ja) * | 2003-03-07 | 2006-09-28 | ガミダ セル リミテッド | Pi3−キナーゼの調節剤を用いた再生可能な幹細胞集団の拡大 |
JP2008509676A (ja) * | 2004-08-13 | 2008-04-03 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | ヒト胚性幹細胞における自己再生および分化のための組成物および方法 |
JP2010539239A (ja) * | 2007-09-17 | 2010-12-16 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害剤としてのピリドピリミジン誘導体 |
JP2011500823A (ja) * | 2007-10-22 | 2011-01-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害物質としてのピリドスルホンアミド誘導体 |
WO2011134979A2 (fr) * | 2010-04-27 | 2011-11-03 | Scil Technology Gmbh | Préparation stable de mia/cd-rap |
JP2012525349A (ja) * | 2009-04-30 | 2012-10-22 | グラクソ グループ リミテッド | Pi3キナーゼ阻害剤としてのオキサゾール置換インダゾール |
WO2013106677A1 (fr) * | 2012-01-13 | 2013-07-18 | The General Hospital Corporation | Cellules progénitrices de poumon humain isolé et leurs utilisations |
-
2013
- 2013-12-20 WO PCT/JP2013/084310 patent/WO2014098232A1/fr active Application Filing
- 2013-12-20 JP JP2014553227A patent/JPWO2014098232A1/ja active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003526679A (ja) * | 2000-03-13 | 2003-09-09 | コリア インスティチュート オブ サイエンス アンド テクノロジー | 各種物質の可溶化用組成物と剤形及びそれらの製造方法 |
JP2006521813A (ja) * | 2003-03-07 | 2006-09-28 | ガミダ セル リミテッド | Pi3−キナーゼの調節剤を用いた再生可能な幹細胞集団の拡大 |
JP2008509676A (ja) * | 2004-08-13 | 2008-04-03 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | ヒト胚性幹細胞における自己再生および分化のための組成物および方法 |
WO2006038552A1 (fr) * | 2004-10-01 | 2006-04-13 | Eisai R & D Management Co., Ltd. | Composition contenant de fines particules et procédé de fabrication de ladite composition |
JP2010539239A (ja) * | 2007-09-17 | 2010-12-16 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害剤としてのピリドピリミジン誘導体 |
JP2011500823A (ja) * | 2007-10-22 | 2011-01-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害物質としてのピリドスルホンアミド誘導体 |
JP2012525349A (ja) * | 2009-04-30 | 2012-10-22 | グラクソ グループ リミテッド | Pi3キナーゼ阻害剤としてのオキサゾール置換インダゾール |
WO2011134979A2 (fr) * | 2010-04-27 | 2011-11-03 | Scil Technology Gmbh | Préparation stable de mia/cd-rap |
WO2013106677A1 (fr) * | 2012-01-13 | 2013-07-18 | The General Hospital Corporation | Cellules progénitrices de poumon humain isolé et leurs utilisations |
Non-Patent Citations (1)
Title |
---|
YANAN Y ET AL.: "Phosphatidylinositol 3-kinase stimulates the proliferation of bronchioalveolar stem cells in mouse models of oncogenic K-ras-induced lung cancer.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 49, 2008, pages 1285 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019031447A (ja) * | 2017-08-04 | 2019-02-28 | タンデム カンパニー,リミテッド | 新規な組換えエキソソーム及びその用途 |
CN115840004A (zh) * | 2022-08-08 | 2023-03-24 | 中国医学科学院基础医学研究所 | 一种检测视黄醇代谢产物的试剂在制备诊断和/或治疗尘肺病工具中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2014098232A1 (ja) | 2017-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6158984B2 (ja) | 吸入可能な医薬組成物 | |
US7476380B2 (en) | Methods for treating illnesses of the tracheo-bronchial tract, especially chronic obstructive pulmonary disease (COPD) | |
Prota et al. | Leucine enhances aerosol performance of naringin dry powder and its activity on cystic fibrosis airway epithelial cells | |
Pilcer et al. | New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients | |
JP2016172777A (ja) | 再発性癌の処置のための方法および組成物 | |
Kadota et al. | Evaluation of highly branched cyclic dextrin in inhalable particles of combined antibiotics for the pulmonary delivery of anti-tuberculosis drugs | |
Minne et al. | Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients | |
CN106659686A (zh) | 用于治疗年龄相关病况的可吸入雷帕霉素制剂 | |
CN103687483A (zh) | 用于呼吸递送两种或多种活性剂的组合物、方法和系统 | |
JP6403686B2 (ja) | 液体局所用医薬ナノエマルジョン製剤 | |
Hertel et al. | Particle engineered mannitol for carrier-based inhalation–A serious alternative? | |
Xu et al. | Influence of excipients on spray-dried powders for inhalation | |
Yao et al. | Inhibition of lanthanide nanocrystal-induced inflammasome activation in macrophages by a surface coating peptide through abrogation of ROS production and TRPM2-mediated Ca2+ influx | |
Huang et al. | Effect of surfactant and budesonide on the pulmonary distribution of fluorescent dye in mice | |
Kramek-Romanowska et al. | Dynamic tensiometry studies on interactions of novel therapeutic inhalable powders with model pulmonary surfactant at the air–water interface | |
Puccetti et al. | Development and in vitro-in vivo performances of an inhalable indole-3-carboxaldehyde dry powder to target pulmonary inflammation and infection | |
van ‘t Veen et al. | Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity | |
WO2014098232A1 (fr) | Composition pharmaceutique comprenant un inhibiteur de kinase pi3, composition pharmaceutique comprenant un composé qui agit sur un récepteur de vitamine d, composition lyophilisée, procédé de production de composition lyophilisée et composition pharmaceutique destinée à être administrée par voie transpulmonaire | |
Deng et al. | Astaxanthin attenuates cigarette smoking-induced oxidative stress and inflammation in a sirtuin 1-dependent manner | |
BR112020020564A2 (pt) | Formulações de ciclosporina para uso no tratamento da síndrome de bronquiolite obliterante (bos) | |
JPH0892098A (ja) | 肺結核治療剤 | |
JP2021502404A (ja) | 線維症の治療のための組成物および方法 | |
Khandouzi et al. | Optimized particle engineering of fluticasone propionate and salmeterol xinafoate by spray drying technique for dry powder inhalation | |
Lee et al. | Bioadhesive drug delivery system using glyceryl monooleate for the intravesical administration of paclitaxel | |
WO2018065917A2 (fr) | Composition de tensioactif pulmonaire synthétique pour le traitement d'affections pulmonaires |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13864499 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2014553227 Country of ref document: JP Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13864499 Country of ref document: EP Kind code of ref document: A1 |